Consolidated Statements of Assets and Liabilities - USD ($) $ in Thousands		Jun. 30, 2025		Dec. 31, 2024
Assets
Investments, at fair value		$ 1,608,953	[1],[2]	$ 1,064,073	[3]
Cash		49,027		19,277
Foreign currency (cost—$656 and $424, respectively)		657		416
Receivable for investments sold and repaid		5,909		216
Income receivable		13,930		10,401
Unrealized appreciation on foreign currency forward contracts		0		200
Deferred financing costs		5,666		3,659
Prepaid expenses and other assets		6,249		254
Total assets		1,690,391		1,098,496
Liabilities
Payable for investments purchased		24,891		23,746
Debt	[4]	507,584		229,355
Unrealized depreciation on foreign currency forward contracts		304		0
Shareholders’ distributions payable		9,577		9,818
Organizational and offering costs payable		440		103
Accrued capital gains incentive fee	[5]	1,965		1,467
Administrative services expense payable		872		365
Accrued accounting and administrative fees		148		83
Interest payable		5,351		3,150
Other accrued expenses and liabilities		1,516		1,167
Total liabilities		552,648		269,254
Commitments and contingencies	[6]
Shareholders’ equity
Common Shares, $0.01 par value, unlimited shares authorized, 38,328,674 and 28,051,771 Class I shares issued and outstanding, respectively		383		281
Capital in excess of par value		1,120,348		815,969
Retained earnings (accumulated deficit)		17,012		12,992
Total shareholders’ equity		1,137,743	[1],[2]	829,242
Total liabilities and shareholders’ equity		$ 1,690,391		$ 1,098,496
Net asset value per share of common shares at period end (in dollars per share)		$ 29.68		$ 29.56
Non-controlled/unaffiliated investments
Assets
Investments, at fair value		$ 1,582,359		$ 1,037,289
Non-controlled/affiliated investments
Assets
Investments, at fair value		8,765		8,841
Controlled/affiliated investments
Assets
Investments, at fair value		$ 17,829		$ 17,943

[1] See Note 8 for additional information regarding the fair value of the Company’s financial instruments.

[2] Security may be an obligation of one or more entities affiliated with the named company.

[3] See Note 8 for additional information regarding the fair value of the Company’s financial instruments.

[4] See Note 9 for a discussion of the Company’s financing arrangements.

[5] See Note 2 for a discussion of the methodology employed by the Company in calculating the capital gains incentive fees.

[6] See Note 10 for a discussion of the Company’s commitments and contingencies.